Buy Salmeterol powder (89365-50-4) hplc≥98% – β-Agonist Wisepowder

Buy Salmeterol powder (89365-50-4) hplc≥98% – β-Agonist Wisepowder https://www.wisepowder.com/product-details/89365-50-4/ Chemical Base Information Name Salmeterol CAS 89365-50-4 Purity 98% Chemical name 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol Synonyms Salmeterol 89365-50-4 Serevent Aeromax Astmerole Molecular Formula C25H37NO4 Molecular Weight 415.574 g/mol Melting Point 75.5-76.5 °C InChI Key…

Buy Salmeterol powder (89365-50-4) hplc≥98% - β-Agonist Wisepowder

Source

0
(0)

Buy Salmeterol powder (89365-50-4) hplc≥98% – β-Agonist Wisepowder

https://www.wisepowder.com/product-details/89365-50-4/

Chemical Base Information
Name Salmeterol
CAS 89365-50-4
Purity 98%
Chemical name 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
Synonyms Salmeterol
89365-50-4

Serevent

Aeromax

Astmerole

Molecular Formula C25H37NO4
Molecular Weight 415.574 g/mol
Melting Point 75.5-76.5 °C
InChI Key GIIZNNXWQWCKIB-UHFFFAOYSA-N
Form Solid
Appearance White
Half Life 5.5 hours
Solubility DMSO: soluble 60 mg/mL, H2O: insoluble
Storage Condition 2-8°C
Application For the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Testing Document Available
03 Salmeterol (89365-50-4) General Description
Salmeterol is a long-acting β2 adrenergic receptor agonist (LABA) used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).

04 Salmeterol (89365-50-4) History
Salmeterol, first marketed and manufactured by Glaxo (now GlaxoSmithKline, GSK) in the 1980s, was released as Serevent in 1990. The product is marketed by GSK under the Allen & Hanburys brand in the UK.

In November 2005, the US Food and Drug Administration released a health advisory, alerting the public to findings that show the use of long-acting β2 agonists could lead to a worsening of symptoms, and in some cases death.

While the use of inhaled LABAs are still recommended in asthma guidelines for the resulting improved symptom control, further concerns have been raised. A large meta-analysis of pooled results from 19 trials with 33,826 participants, suggests that salmeterol may increase the small risks of asthma-related deaths, and this additional risk is not reduced with the additional use of inhaled steroids (e.g., as with the combination product fluticasone/salmeterol). This seems to occur because although LABAs relieve asthma symptoms, they also promote bronchial inflammation and sensitivity without warning.

0 / 5. 0

Leave a Reply